Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1921 1
1925 1
1926 1
1931 1
1933 2
1934 1
1938 1
1939 2
1940 1
1941 2
1942 3
1943 1
1945 8
1946 19
1947 8
1948 15
1949 19
1950 11
1951 11
1952 17
1953 16
1954 11
1955 11
1956 20
1957 12
1958 11
1959 9
1960 9
1961 15
1962 13
1963 13
1964 12
1965 12
1966 20
1967 23
1968 28
1969 29
1970 36
1971 47
1972 37
1973 43
1974 47
1975 57
1976 54
1977 62
1978 80
1979 77
1980 105
1981 98
1982 105
1983 102
1984 103
1985 124
1986 132
1987 139
1988 166
1989 205
1990 205
1991 207
1992 242
1993 258
1994 240
1995 271
1996 255
1997 255
1998 260
1999 250
2000 279
2001 299
2002 298
2003 301
2004 339
2005 383
2006 421
2007 433
2008 493
2009 528
2010 548
2011 617
2012 635
2013 620
2014 698
2015 705
2016 719
2017 741
2018 717
2019 776
2020 847
2021 862
2022 844
2023 217
Text availability
Article attribute
Article type
Publication date

Search Results

16,470 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude EB, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Rice ASC, Bouhassira D, Bennett DL, Selvarajah D; OPTION-DM trial group. Tesfaye S, et al. Among authors: johnson m. Lancet. 2022 Aug 27;400(10353):680-690. doi: 10.1016/S0140-6736(22)01472-6. Epub 2022 Aug 22. Lancet. 2022. PMID: 36007534 Free PMC article. Clinical Trial.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Johnson ML, et al. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3. J Clin Oncol. 2023. PMID: 36327426 Free PMC article. Clinical Trial.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Among authors: johnson m. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
Structural basis for SHOC2 modulation of RAS signalling.
Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J. Liau NPD, et al. Among authors: johnson mc. Nature. 2022 Sep;609(7926):400-407. doi: 10.1038/s41586-022-04838-3. Epub 2022 Jun 29. Nature. 2022. PMID: 35768504 Free PMC article.
A synergistic mindsets intervention protects adolescents from stress.
Yeager DS, Bryan CJ, Gross JJ, Murray JS, Krettek Cobb D, H F Santos P, Gravelding H, Johnson M, Jamieson JP. Yeager DS, et al. Among authors: johnson m. Nature. 2022 Jul;607(7919):512-520. doi: 10.1038/s41586-022-04907-7. Epub 2022 Jul 6. Nature. 2022. PMID: 35794485 Free PMC article. Clinical Trial.
Dairying, diseases and the evolution of lactase persistence in Europe.
Evershed RP, Davey Smith G, Roffet-Salque M, Timpson A, Diekmann Y, Lyon MS, Cramp LJE, Casanova E, Smyth J, Whelton HL, Dunne J, Brychova V, Šoberl L, Gerbault P, Gillis RE, Heyd V, Johnson E, Kendall I, Manning K, Marciniak A, Outram AK, Vigne JD, Shennan S, Bevan A, Colledge S, Allason-Jones L, Amkreutz L, Anders A, Arbogast RM, Bălăşescu A, Bánffy E, Barclay A, Behrens A, Bogucki P, Carrancho Alonso Á, Carretero JM, Cavanagh N, Claßen E, Collado Giraldo H, Conrad M, Csengeri P, Czerniak L, Dębiec M, Denaire A, Domboróczki L, Donald C, Ebert J, Evans C, Francés-Negro M, Gronenborn D, Haack F, Halle M, Hamon C, Hülshoff R, Ilett M, Iriarte E, Jakucs J, Jeunesse C, Johnson M, Jones AM, Karul N, Kiosak D, Kotova N, Krause R, Kretschmer S, Krüger M, Lefranc P, Lelong O, Lenneis E, Logvin A, Lüth F, Marton T, Marley J, Mortimer R, Oosterbeek L, Oross K, Pavúk J, Pechtl J, Pétrequin P, Pollard J, Pollard R, Powlesland D, Pyzel J, Raczky P, Richardson A, Rowe P, Rowland S, Rowlandson I, Saile T, Sebők K, Schier W, Schmalfuß G, Sharapova S, Sharp H, Sheridan A, Shevnina I, Sobkowiak-Tabaka I, Stadler P, Stäuble H, Stobbe A, Stojanovski D, Tasić N, van Wijk I, Vostrovská I, Vukov… See abstract for full author list ➔ Evershed RP, et al. Among authors: johnson m. Nature. 2022 Aug;608(7922):336-345. doi: 10.1038/s41586-022-05010-7. Epub 2022 Jul 27. Nature. 2022. PMID: 35896751
Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial.
Ekström M, Ferreira D, Chang S, Louw S, Johnson MJ, Eckert DJ, Fazekas B, Clark KJ, Agar MR, Currow DC; Australian National Palliative Care Clinical Studies Collaborative. Ekström M, et al. Among authors: johnson mj. JAMA. 2022 Nov 22;328(20):2022-2032. doi: 10.1001/jama.2022.20206. JAMA. 2022. PMID: 36413230 Clinical Trial.
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.
Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, Parkhurst MR, Gartner JJ, Prickett TD, Lowery FJ, Kishton RJ, Gurusamy D, Franco Z, Vodnala SK, Diers MD, Wolf NK, Slipek NJ, McKenna DH, Sumstad D, Viney L, Henley T, Bürckstümmer T, Baker O, Hu Y, Yan C, Meerzaman D, Padhan K, Lo W, Malekzadeh P, Jia L, Deniger DC, Patel SJ, Robbins PF, McIvor RS, Choudhry M, Rosenberg SA, Moriarity BS, Restifo NP. Palmer DC, et al. Among authors: johnson mj. Med (N Y). 2022 Oct 14;3(10):682-704.e8. doi: 10.1016/j.medj.2022.07.008. Epub 2022 Aug 24. Med (N Y). 2022. PMID: 36007524 Free article.
Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: johnson ml. J Clin Oncol. 2023 Jan 23:JCO2202823. doi: 10.1200/JCO.22.02823. Online ahead of print. J Clin Oncol. 2023. PMID: 36689692
16,470 results
You have reached the last available page of results. Please see the User Guide for more information.